Presbyopia

LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference

Retrieved on: 
torsdag, maj 30, 2024
Conference, Presbyopia, Therapy, Webcast, SAN

SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that Eef Schimmelpennink, President and Chief Executive Officer, will present and company management will participate in one-on-one meetings at the Jefferies Global Healthcare Conference being held from June 5th- 6th, 2024 in New York City.

Key Points: 
  • SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that Eef Schimmelpennink, President and Chief Executive Officer, will present and company management will participate in one-on-one meetings at the Jefferies Global Healthcare Conference being held from June 5th- 6th, 2024 in New York City.
  • Details of the event are as follows:
    The live audio webcast of the presentation can be accessed on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section.
  • A replay of the webcast will be available on the Company’s website for 30 days following the event.

Bausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens

Retrieved on: 
tisdag, maj 28, 2024
Biotechnology, Pharmaceutical, Optical, Health, FDA, Medical Devices, Clinical Trials, Other Health, Presbyopia, Patient, Cataract, University, Envy, Astigmatism, Sale, Trial of the century, GLARE, DSM-IV codes, Contact, Dioptre, Bausch & Lomb, Health Canada, Freedom

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens (IOL).

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens (IOL).
  • This is the first global regulatory approval of the new lens, which offers a full range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform.
  • “enVista Envy is the next step in the dramatic transformation of our IOL portfolio,” said Luc Bonnefoy, president, Global Surgical, Bausch + Lomb.
  • Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets, including the U.S. and Europe.

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
onsdag, maj 8, 2024
FDA, New Drug Application, Presbyopia, Phase 3, Therapy, Patient, Pharmaceutical industry

ET

Key Points: 
  • ET
    SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today reported financial results and operational highlights for the first quarter ended March 31, 2024.
  • In February 2024, LENZ launched its unbranded “Eye Am…” campaign to educate and excite eye care professionals about future presbyopia solutions.
  • In March 2024, LENZ Therapeutics announced completion of its merger with Graphite Bio, Inc. and the concurrent $53.5 million private placement, commencing trading on the Nasdaq Global Select Market under the ticker symbol “LENZ” on March 21, 2024.
  • The live webcast from today’s conference call can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section.

STAAR Surgical Reports First Quarter 2024 Results

Retrieved on: 
tisdag, maj 7, 2024
General Health, Surgery, Medical Devices, Health, Optical, Sale, Near-sightedness, Table, IOL, Presbyopia, Investment, EVO, Research, Depreciation, STAAR, ICL, Patient, Access, Marketing, Adjustment, Fruit, Cataract, Advertising, Astigmatism, GAAP, Growth

STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024.

Key Points: 
  • STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024.
  • Gross profit margin for the first quarter of 2024 was 78.9% of net sales compared to the prior year quarter of 78.3% of net sales.
  • Product and country mix favorably impacted gross margin in the first quarter of 2024 as compared to the prior year quarter.
  • Operating expenses for the first quarter of 2024 were $63.3 million compared to the prior year quarter of $54.8 million.

STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision

Retrieved on: 
tisdag, maj 7, 2024
Optical, Health, Surgery, Medical Devices, Education, Near-sightedness, Left, Presbyopia, EVO, Refractive surgery, Cataract, PIB, STAAR, Surgeon, Nave, MD, Quality, ICL, Contact, Chairperson, Lens, ASCRS, Eye, Society, Athlete, Multimedia, Marketing, SMILE, Astigmatism, Growth, Telescopic sight

View the full release here: https://www.businesswire.com/news/home/20240507036972/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240507036972/en/
    Tom Frinzi, Chair of the Board, President and CEO, STAAR Surgical (Left) and Dr. Robert T. Lin, founder and surgeon, IQ Laser Vision (Right).
  • (Photo: Business Wire)
    IQ Laser Vision will make EVO ICL lenses a primary option for patients seeking surgical vision correction within the range of -3D to -20D, as part of its comprehensive refractive offering.
  • IQ Laser Vision intends to nearly double its volume in EVO ICLs over the course of the next 12 months.
  • Today, we’re thrilled to announce that IQ Laser Vision has joined our U.S. Highway 93 program with the largest agreement for EVO ICL in the U.S. thus far.

Clear Eyesight Takes Huge Leap Forward with New Odyssey "Permanent Vision Correction Lens"

Retrieved on: 
tisdag, maj 7, 2024
Presbyopia, Health, Johnson & Johnson, LeBron James, Water, RLE, DRS, Lens, Aram, Patient, Eye, Approximation error, Ophthalmology, Telescopic sight

But with the new Odyssey lens, patients can achieve near-LASIK quality vision with an intraocular lens (IOL) for the first time.

Key Points: 
  • But with the new Odyssey lens, patients can achieve near-LASIK quality vision with an intraocular lens (IOL) for the first time.
  • "This state-of-the-art lens achieves fantastic vision across multiple focal points, like a healthy natural lens in the eye is capable of.
  • Thus, making the Odyssey a great option for those who are not good candidates for LASIK laser eye surgery."
  • Aram, 56 , a civil engineer, wanted to wait for more data before trying the state-of-the-art Odyssey lens.

STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

Retrieved on: 
onsdag, maj 1, 2024
Optical, Health, Surgery, Medical Devices, Corporation, Science, Medtech, Near-sightedness, Law, University, Presbyopia, American Tower, Believer, EVO, General counsel, OTC, Marketing, Commerce, Johnson & Johnson, STAAR, Surgeon, University School, Business, Partner (business rank), CareFusion, Contact, Duke University, NuVasive, Senior, Patient, Multimedia, Global marketing, Emory University, Associate, Astigmatism, Economics, Nate, Growth, Engineering, Management

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.
  • View the full release here: https://www.businesswire.com/news/home/20240501408389/en/
    “We are thrilled to strengthen the STAAR team with the addition of Nancy and Nate, two seasoned executives with extensive senior leadership experience.
  • “Nancy is a perfect fit for the newly created Chief Marketing Officer position and will be critical to driving our brand awareness and innovation globally.
  • “I am thrilled to join the STAAR leadership team at a time of significant opportunity and growth for our vision correction lenses,” said Nate Sisitsky.

STAAR Surgical to Report First Quarter Results on May 7, 2024

Retrieved on: 
måndag, april 29, 2024
Optical, Health, Surgery, Medical Devices, Near-sightedness, STAAR, Presbyopia, Astigmatism, Webcast, EVO

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.
  • STAAR will host a conference call and webcast on Tuesday, May 7 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress.
  • To access the conference call please dial 833-816-1164 for domestic participants and 412-317-1899 for international participants.
  • The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com .

Ace Vision Group Names Ken Araki to Its Board of Directors

Retrieved on: 
fredag, april 5, 2024
Takeda Pharmaceutical Company, Presbyopia, Patient, Quality of life, Eye, LSM, FDA, Ageing, Ophthalmology, Pharmaceutical industry

BOSTON, April 5, 2024 /PRNewswire/ -- Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye, today announced that it has named Ken Araki to its board of directors.

Key Points: 
  • BOSTON, April 5, 2024 /PRNewswire/ -- Ace Vision Group, Inc ., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye, today announced that it has named Ken Araki to its board of directors.
  • Mr. Araki brings executive management experience and strategic leadership skills to support and drive commercial planning for the VisioLite® laser.
  • "As we prepare for commercialization of this ground-breaking ophthalmic laser therapeutic for the age-related vision loss that comes with presbyopia, Ken is an important addition to our team," said Dr. AnnMarie Hipsley, CEO of Ace Vision Group.
  • "I look forward to working with Ace Vision Group to offer new and innovative solutions for presbyopia," said Araki.

STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024

Retrieved on: 
torsdag, april 4, 2024
Optical, Health, Surgery, Medical Devices, ICL, U.S. FDA, Growth, Presbyopia, Near-sightedness, Sale, EVO, Bank statement, Investment, FDA, Astigmatism

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter.
  • “STAAR is off to a solid start in 2024 as illustrated by our preliminary first quarter results including a record quarter in the U.S.,” said Tom Frinzi, President and CEO of STAAR Surgical.
  • ICL sales were up approximately 20% sequentially to $5 million in the first quarter, which reflects early signs of our increased market focus.
  • The Company expects to report complete first quarter financial results and discuss its fiscal 2024 outlook during its quarterly earnings call on or about May 8, 2024.